TRANSCEND-T2D-1: Results of First Phase 3 Study of Retatrutide, a GIP,GLP-1, and Glucagon Receptor Agonist in Patientswith T2D
by Prateek Chopra | June 29, 2026 | Diabetes Conferences | ADA 2026 Trial Overview Study Design Glycemic Outcomes Weight Loss Outcomes Cardiometabolic Benefits Safety Outcomes Clinical Implications In the TRANSCEND-T2D-1 trial, retatrutide produced substantial reductions in HbA1c and body weight, along with improvements in cardiovascular risk factors. These findings support its potential as an effective treatment option for managing […]